Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 2:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PET/MRI imaging Clear all
Terminated No phase listed Observational

Imaging a Cholinergic Biomarker of Cognition in Parkinson's Disease

NCT05034263
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
Stony Brook University
Other
Eligibility
50 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 25, 2026, 2:42 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

NCT04692103
View directory record Official record
Conditions
Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Computed Tomography, Fludeoxyglucose F-18, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2041
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 25, 2026, 2:42 PM EDT
Recruiting Phase 1 Interventional

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

NCT07217028
View directory record Official record
Conditions
SCC - Squamous Cell Carcinoma, Radiotracer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Interventions
Cetuximab (EGFR inhibitor), 18F-NOTA-ABY-030, Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 25, 2026, 2:42 PM EDT
Recruiting Phase 2 Interventional

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

NCT05873712
View directory record Official record
Conditions
Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Transformed
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Fludarabine, Leukapheresis, Lisocabtagene Maraleucel, Lymph Node Biopsy, Positron Emission Tomography, Zanubrutinib
Procedure · Drug · Biological
Lead sponsor
Aseel Alsouqi
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
New York, New York • Columbus, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 25, 2026, 2:42 PM EDT
Terminated Phase 2 Interventional

68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy

NCT04928820
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Sep 25, 2026, 2:42 PM EDT
Completed Not applicable Interventional

Choline PET/CT and MRI for Targeted Prostate Biopsy

NCT01751737
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate Cancer Imaging
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
40 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Sep 25, 2026, 2:42 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

NCT04385277
View directory record Official record
Conditions
Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, FDG-Positron Emission Tomography, Iobenguane I-123, Irinotecan, Isotretinoin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sargramostim, Temozolomide
Procedure · Biological · Radiation + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
70
States / cities
Mesa, Arizona • Little Rock, Arkansas • Downey, California + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 25, 2026, 2:42 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT04600115
View directory record Official record
Conditions
MRI Scans
Interventions
Adenosine, Regadenoson, O-15 labeled radioactive water, MRI, PET Imaging
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 25, 2026, 2:42 PM EDT
Completed Not applicable Interventional

18F-FDG PET-MRI for Planning and Follow-Up of Patients With Spine Tumors Treated With Spine Stereotactic Radiosurgery

NCT05174026
View directory record Official record
Conditions
Metastatic Malignant Neoplasm, Metastatic Malignant Neoplasm in the Bone
Interventions
Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 25, 2026, 2:42 PM EDT
Completed Not applicable Interventional

Evaluation of PET/MRI in Children With Cancer

NCT01839747
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
PET-MRI, PET-CT
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced Sep 25, 2026, 2:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Changes in Dopamine Levels Before and After Weight Restoration in People With Anorexia Nervosa

NCT00670293
View directory record Official record
Conditions
Eating Disorders
Interventions
Positron Emission Tomography (PET) using [11C]raclopride, Methylphenidate, Magnetic Resonance Imaging (MRI) scan
Radiation · Drug · Procedure
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Sep 25, 2026, 2:42 PM EDT
Completed Phase 1 Interventional

Arterial Imaging of Inflammation and Resolution After Endovascular Surgery

NCT03590769
View directory record Official record
Conditions
Peripheral Arterial Disease, Claudication, Intermittent, Claudication, PAD, SFA - Superficial Femoral Artery Stenosis, Iliac Artery Disease, Vascular Calcification
Interventions
18F-FDG
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2020 · Synced Sep 25, 2026, 2:42 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

NCT02918357
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ga-68 labeled PSMA-11 PET
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2019 · Synced Sep 25, 2026, 2:42 PM EDT
Completed Early Phase 1 Interventional

BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy

NCT05250895
View directory record Official record
Conditions
BCLC Stage a Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatocellular Carcinoma
Interventions
18F-Fluoromisonidazole, Biopsy, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Positron Emission Tomography
Other · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 25, 2026, 2:42 PM EDT
Completed Early Phase 1 Interventional

Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer

NCT02420977
View directory record Official record
Conditions
Advanced Prostate Cancer
Interventions
Pelvic DCFPyL PET-MRI fusion or PET/MRI
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 25, 2026, 2:42 PM EDT
Not listed Phase 2 Interventional

68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer

NCT02282137
View directory record Official record
Conditions
Prostate Cancer
Interventions
68Ga-PSMA
Drug
Lead sponsor
Ebrahim Delpassand
Other
Eligibility
18 Years and older · Male only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Sep 25, 2026, 2:42 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

NCT07281417
View directory record Official record
Conditions
Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8, Stage IVA Sinonasal Cancer AJCC v8, Stage IVB Sinonasal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Carboplatin, Cemiplimab, Chemoradiotherapy, Cisplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Radiation Therapy, Surgical Procedure
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
14
States / cities
Irvine, California • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 25, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Results available

Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI

NCT03404648
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
C-11 choline PET tracer, Gadobutrol, PET/MR scanner
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 7, 2021 · Synced Sep 25, 2026, 2:42 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15

NCT06032026
View directory record Official record
Conditions
Tauopathies
Interventions
11C-HY-2-15 PET, brain MRI, Amyloid PET scan, Neurological assessments
Drug · Diagnostic Test · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Sep 25, 2026, 2:42 PM EDT
Completed No phase listed Observational

Positron Emission Tomography (PET) Using Hormone Receptor Ligands in Breast Cancer

NCT00647790
View directory record Official record
Conditions
Breast Cancer
Interventions
PET scan with injection of 5-8 mCi of 18FES
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2015 · Synced Sep 25, 2026, 2:42 PM EDT
Active, not recruiting Phase 2 Interventional

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

NCT02849496
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma, Metastatic Breast Carcinoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Positron Emission Tomography, Questionnaire Administration, X-Ray Imaging
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
58
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 25, 2026, 2:42 PM EDT
Recruiting Phase 2 Interventional

[18F]FES PET/.CT in Uterine Cancer

NCT05916196
View directory record Official record
Conditions
Uterine Cancer
Interventions
18F-Fluoroestradiol
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 25, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Brain Imaging and Retreatment Study of Persistent Lyme Disease

NCT00037479
View directory record Official record
Conditions
Lyme Disease, Lyme Neuroborreliosis
Interventions
ceftriaxone
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2005 · Synced Sep 25, 2026, 2:42 PM EDT
Recruiting Phase 3 Interventional

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NCT06172296
View directory record Official record
Conditions
Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dinutuximab, Doxorubicin, Echocardiography Test, Etoposide, FDG-Positron Emission Tomography and Computed Tomography Scan, Hematopoietic Cell Transplantation, Irinotecan, Isotretinoin, Leukapheresis, Magnetic Resonance Imaging, Melphalan, Multigated Acquisition Scan, Radiation Therapy, Radionuclide Imaging, Survey Administration, Temozolomide, Thiotepa, Topotecan, Tumor Resection, Vincristine
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
157
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 127 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 25, 2026, 2:42 PM EDT